Please check your internet connection and try again.
# Calcium acetate
## Overview
Calcium acetate is a phosphate binder that reacts with dietary phosphate in the gastrointestinal tract to form insoluble calcium phosphate, which is then excreted in feces. It provides a higher calcium content per gram than other calcium salts.
## Primary Indications
* Management of hyperphosphatemia in end-stage renal disease (ESRD).
## Adult Dosing
* **Initial Dose:** 1,334 mg (2 capsules or 1 tablet) orally with each meal.
* **Titration:** Increase slowly based on serum phosphate levels to lower levels to an acceptable range (typically < 6.0 mg/dL).
* **Maximum Dose:** Generally 6,000 mg to 8,000 mg daily, though titration must be patient-specific to avoid hypercalcemia.
## Pediatric Dosing
* **Dosing:** Not well-established. If used, dosing is off-label and varies by institution.
* **General Approach:** Usually initiated at 200–500 mg per dose with meals, titrating based on serum phosphate and calcium levels. Pediatric nephrology consultation is required.
## Dose Adjustments
* **Hypercalcemia:** If serum calcium levels exceed the desired range, reduce or temporarily discontinue the dose.
* **Parenteral/Other:* If switching from another phosphate binder, dosage will vary significantly based on elemental calcium content.
## Contraindications
* Hypercalcemia.
* Hypophosphatemia.
* Severe renal calculi (nephrolithiasis).
## Adverse Effects
* **Most Common:** Hypercalcemia (manifesting as nausea, constipation, confusion, or cardiac arrhythmias).
* **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain.
* **Other:** Pruritus/rash.
## Key Drug Interactions
* **Tetracyclines/Doxycycline:** Reduced absorption; administer calcium acetate 2 hours before or 4–6 hours after.
* **Fluoroquinolones (e.g., Ciprofloxacin):** Reduced absorption; administer at least 2 hours before or 6 hours after.
* **Levothyroxine:** Reduced absorption; separate dosing by 4 hours.
* **Bisphosphonates:** Reduced absorption; separate dosing by at least 2 hours.
## Monitoring
* **Serum Phosphorus:** Monitor at least every 2–4 weeks initially, then periodically once stable.
* **Serum Calcium:** Monitor weekly during initiation and dose titration; monthly thereafter.
* **Calcium-Phosphorus Product (Ca x P):** Monitor to reduce risk of soft tissue mineralization; goal is generally < 55 mg²/dL².
## Clinical Pearls
* **Administration:** Must be taken with meals to effectively bind dietary phosphate.
* **Hypercalcemia Risk:** Calcium acetate carries a higher risk of hypercalcemia compared to sevelamer (a non-calcium-based binder).
* **Patient Education:** Advise patients to avoid taking additional calcium supplements or vitamin D analogues without physician oversight, as this exponentially increases hypercalcemia risk.
***
*Disclaimer: This information is for educational purposes only. Clinical practices vary by facility; always verify specific dosing, safety protocols, and drug compatibility with current institutional guidelines and official prescribing information (package insert) before administration.*
